The Inflammasome Deep Dive: NLRP3, NLRP6 and the Resolution Machinery
Inflammasomes are protein complexes inside cells that sense infection and damage and switch on caspase-1, an enzyme that releases the inflammatory signals IL-1β and IL-18. NLRP3 is the best-studied one and responds to many kinds of cellular stress. NLRP6 has been studied mainly in the gut lining of mice. Separate resolution signals help bring inflammation to an end.
Gout is one of the oldest described forms of arthritis, and its link to uric acid crystals in the joint has been known for generations. Why a crystal should set off such a fierce reaction took much longer to work out. In 2006, Fabio Martinon, Jürg Tschopp and colleagues showed that gout-associated uric acid crystals activate an immune sensor then called NALP3, now NLRP3, and that the sensor was needed for the crystals to release IL-1β from immune cells.
The same group had named the inflammasome four years earlier. Since then the field has grown into a family of sensors, each wired to its own part of the body, and a second line of research has asked a different question: once the alarm has done its job, what turns it off?
A Building With More Than One Alarm
A large building rarely relies on one smoke detector. It has sensors on every floor, each tuned to the room it watches, all feeding the same panel. A good system also has a crew that resets the panel once the danger is gone. That is a fair picture of the inflammasome field: several sensors, a shared alarm, and a separate reset crew.
The sensors belong to the NLR family, proteins that sit inside cells and watch for signs of trouble. When one is set off, it recruits an adapter protein called ASC, and ASC pulls in pro-caspase-1. The parts snap together into a single cluster, and caspase-1 becomes active. The first inflammasome Tschopp's team characterized was built on NLRP1, then called NALP1. NLRP3 builds the same kind of platform, and our explainer on the inflammasome covers the basics in plain terms [link: H2-07].
Active caspase-1 does two things. It cuts pro-IL-1β and pro-IL-18 into their working forms, and it cuts a protein called gasdermin D. The freed fragment of gasdermin D punches pores in the cell's outer membrane, and the cell swells and bursts. This form of cell death is called pyroptosis. Apoptosis, the cell's orderly shutdown, packages the cell for quiet removal. Pyroptosis spills the cell's contents into the tissue, where they can act as fresh warning signals for neighboring cells.
NLRP3: The Detector That Reads General Stress
NLRP3 runs on a two-signal design. The first signal, priming, comes from warning signs such as lipopolysaccharide (LPS), a fragment of bacterial cell walls, or from inflammatory cytokines such as TNF. Priming tells the cell to make more NLRP3 and to stock pro-IL-1β. The second signal triggers assembly. Many unrelated inputs qualify: potassium leaking out of the cell, ATP spilling from damaged neighbors, reactive oxygen from stressed mitochondria, and swallowed crystals of uric acid or cholesterol. Potassium efflux is a common step downstream of many of these triggers, which helps explain why chemically different stresses converge on one complex.
That breadth is what makes NLRP3 interesting for aging research. Franceschi and colleagues coined "inflamm-aging" in 2000 for the chronic, low-grade inflammation that tends to build with age. Several things that accumulate over the years, including cholesterol crystals, misfolded protein aggregates and damaged mitochondria, are recognized NLRP3 triggers in experimental systems. Our piece on inflammaging follows that thread [link].
Human genetics supplied the clearest early evidence. In 2001, Hoffman and colleagues traced familial cold autoinflammatory syndrome and Muckle-Wells syndrome to changes in a then-new gene, now called NLRP3. In these families, cold exposure could bring on rash and fever. The changes make the sensor fire too easily, and the conditions are now grouped as cryopyrin-associated periodic syndromes (CAPS).
NLRP3 in the Brain
The brain's resident immune cells, microglia, carry NLRP3. In 2013, Michael Heneka and colleagues reported NLRP3 inflammasome activation in post-mortem brain tissue from people with Alzheimer's disease. They then studied APP/PS1 mice, which are bred to build up amyloid-beta. Mice of this model that also lacked NLRP3 or caspase-1 were largely protected from the spatial memory problems the model develops, and their microglia cleared more amyloid. The human part of that work is observational; the protection was seen in mice.
Since then, NLRP3 has become a common subject in research on brain aging, alongside the question of how inflammation elsewhere in the body reaches the brain, which our piece on the blood-brain barrier covers more.
What Drug Trials Have Shown in People
The human evidence for acting on this pathway comes from prescription drugs. In June 2009, the FDA approved canakinumab, an antibody against IL-1β, for CAPS. For families whose sensor is stuck near "on," blocking its main output became an approved therapy.
Cardiology came next. In CANTOS, more than 10,000 people who had had a heart attack and still showed elevated hsCRPreceived canakinumab or placebo. At the 150 mg dose, about 15% fewer had a heart attack, stroke or cardiovascular death. All-cause mortality did not differ, and fatal infections were more common with canakinumab. Canakinumab acts downstream of the inflammasome, on IL-1β itself.
Colchicine, an old gout medicine, damps several inflammatory pathways, inflammasome assembly among them. In COLCOT, low-dose colchicine lowered cardiovascular events by about 23% in people with a recent heart attack. In LoDoCo2, among 5,522 people with chronic coronary disease, colchicine 0.5 mg daily lowered events by about 31%. In June 2023, the FDA approved low-dose colchicine to reduce cardiovascular events in adults with established atherosclerotic disease or multiple risk factors. These trials measured heart attacks and strokes, so they describe arteries, not memory. Drugs designed to block NLRP3 itself, rather than its output, are in clinical development.
NLRP6: A Sensor Studied in the Gut
NLRP6 is a close relative of NLRP3 that has been studied mainly in the lining of the intestine In 2011, Eran Elinav, Richard Flavell and colleagues reported in mice that the NLRP6 inflammasome regulates the microbial ecology of the colon and the risk of colitis, an experimental form of colon inflammation. That finding pointed to an inflammasome that helps shape which microbes live alongside the gut lining.
Later work tested the microbiota part of that picture with tighter controls. In 2017, Michail Mamantopoulos, Andy Wullaert and colleagues reported that Nlrp6- and ASC-dependent inflammasomes did not shape the composition of the commensal gut microbiota in their mouse studies. Both papers come from mouse studies. Our piece on the gut–brain axis covers the wider gut story.
The Reset Crew: How Inflammation Resolves
Every alarm system needs a way to stand down, and for decades researchers assumed inflammation simply faded once its triggers ran out. Work from Charles Serhan's lab described resolution as an active program with its own chemical signals.
The first clue came from timing. In 2001, Serhan's team sampled fluid from an inflamed pocket under the skin of mice over several days. Early on, the cells made leukotriene B4, which calls in more neutrophils. In human immune cells in the lab, prostaglandin E2 switched their output from leukotriene B4 to lipoxin A4, a signal that helps wind the response down. The team called this class switching: the reset is prepared while the alarm is still sounding.
Lipoxins belong to a group called specialized pro-resolving mediators, or SPMs, along with resolvins, protectins and maresins. Lipoxins are made from arachidonic acid, an omega-6 fat; resolvins come from EPA and DHA, and protectins and maresins from DHA. In mice with inflamed abdominal linings, maresin 1 reduced the number of neutrophils flooding in, and in lab tests it made macrophages better at engulfing dying neutrophils.
That engulfing step, efferocytosis, connects resolution back to the way cells die. A cell that dies by apoptosis is packaged for quiet removal. In a 1998 study, human macrophages that had swallowed apoptotic cells made less IL-1β and TNF-alpha and more TGF-beta, a signal tied to calming the response and repairing tissue. A cell that bursts by pyroptosis spills its contents instead. So apoptosis tends to support the cleanup, while pyroptosis can add to the alarm.
How much SPM human blood carries is debated. A 2015 study of 12 volunteers given fish oil found no consistent rise in blood or urine, while a 2020 randomized, placebo-controlled study reported rises after enriched marine oil supplements. Our deep dive on SPMs covers the measurement exchange in full.
What You Can Work On
No routine blood test reads your inflammasomes. hsCRP is a general marker of inflammation with established cardiovascular risk categories, and your clinician can decide whether it adds anything to your care.
Sleep is a practical place to start. In a meta-analysis of 72 studies with more than 50,000 participants, sleep disturbance was linked with higher CRP and IL-6. The 2024 Lancet Commission on dementia named 14 modifiable risk factors, including physical inactivity, high blood pressure, diabetes and high LDL cholesterol, and estimated that about 45% of dementia could in theory be prevented or delayed by addressing all 14. Several of those are numbers you can check with your clinician.
Ask your clinician
- Would an hsCRP test help us understand my heart risk?
- Are my blood pressure, blood sugar and LDL cholesterol where you'd like them?
- Could my sleep be checked for sleep apnea?
In Uno Protect
In Uno Protect: Each 1.7 fl oz (50 mL) bottle provides 871 mg of omega-3s (600 mg DHA and 174 mg EPA) from ROMEGA® herring roe. Omega-3s in the phospholipid form found in fish roe.
Frequently Asked Questions
What is the difference between NLRP3 and NLRP6?
Both are sensors that can build an inflammasome with the adapter ASC and caspase-1. NLRP3 responds to many kinds of cellular stress, including crystals, ATP and potassium loss, and is studied across the body and brain. NLRP6 has been studied mainly in the intestinal lining of mice.
How does inflammation resolve?
In cell and animal studies, the body makes pro-resolving signals, including lipoxins, resolvins, protectins and maresins, that slow the arrival of new immune cells and help macrophages clear spent cells. Clearing apoptotic cells also shifts macrophages toward calming, repair-related signals.
What does pyroptosis mean?
It's a form of cell death in which caspase-1 cuts gasdermin D, the freed fragment opens pores in the cell membrane, and the cell bursts and releases IL-1β, IL-18 and other contents into the tissue.

About the author
Joel Totoro, RD
Joel Totoro, RD, is the Vice President of Nutrition at Bevimi and a registered dietitian and pioneer in sports nutrition and human performance. Totoro brings more than 20 years of experience helping elite athletes and high performers optimize their health, performance, and recovery through evidence-based nutrition.
Clinical References
- Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi:10.1038/nature04516
- Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-426. doi:10.1016/S1097-2765(02)00599-3
- Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477-489. doi:10.1038/s41577-019-0165-0
- Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526(7575):660-665. doi:10.1038/nature15514
- Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-254. doi:10.1111/j.1749-6632.2000.tb06651.x
- Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29(3):301-305. doi:10.1038/ng756
- Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674-678. doi:10.1038/nature11729
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
- Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497-2505. doi:10.1056/NEJMoa1912388
- Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838-1847. doi:10.1056/NEJMoa2021372
- Elinav E, Strowig T, Kau AL, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell. 2011;145(5):745-757. doi:10.1016/j.cell.2011.04.022
- Mamantopoulos M, Ronchi F, Van Hauwermeiren F, et al. Nlrp6- and ASC-dependent inflammasomes do not shape the commensal gut microbiota composition. Immunity. 2017;47(2):339-348.e4. doi:10.1016/j.immuni.2017.07.011
- Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92-101. doi:10.1038/nature13479
- Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612-619. doi:10.1038/89759
- Serhan CN, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009;206(1):15-23. doi:10.1084/jem.20081851
- Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. doi:10.1016/S0140-6736(24)01296-0